crucell

As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell -- in spite of Crucell's recent manufacturing troubles.

Giant drugmaker Johnson & Johnson has agreed to buy Dutch vaccine maker Crucell. The deal will give J&J a bigger piece of the vaccine market and better access to emerging markets.

Still in hot water over its "phantom recall" of a Motrin product, Johnson & Johnson looks to expand its share of the vaccine market with purchase of Dutch pharma company Crucell.

Novavax (NVAX) shares soared some 10 percent today after the small clinical-stage biotechnology company announced positive preclinical results for its new vaccine H1N1 influenza, or swine flu. Novovax, based in Rockville, Maryland, developed the vaccine using proprietary virus-like particle (VLP)...